Home > Institute Collections > BN DZNE > BN DZNE-LIS > Subversion of early innate antiviral responses during antibody-dependent enhancement of Dengue virus infection induces severe disease in immunocompetent mice > print

001     284095
005     20260126111648.0
024 7 _ |a 10.1007/s00430-014-0334-5
|2 doi
024 7 _ |a 0300-8584
|2 ISSN
024 7 _ |a 0044-3077
|2 ISSN
024 7 _ |a 0340-1782
|2 ISSN
024 7 _ |a 1432-1831
|2 ISSN
024 7 _ |a 2199-2983
|2 ISSN
037 _ _ |a DZNE-2026-00103
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Costa, Vivian V.
|b 0
245 _ _ |a Subversion of early innate antiviral responses during antibody-dependent enhancement of Dengue virus infection induces severe disease in immunocompetent mice
260 _ _ |a Heidelberg
|c 2014
|b Springer
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1769422569_1864
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Dengue is a mosquito-borne disease caused by one of four serotypes of Dengue virus (DENV-1-4). Epidemiologic and observational studies demonstrate that the majority of severe dengue cases, dengue hemorrhagic fever and dengue shock syndrome (DHF/DSS), occurs predominantly in either individuals with cross-reactive immunity following a secondary heterologous infection or in infants with primary DENV infections born from dengue-immune mothers, suggesting that B-cell-mediated and antibody responses impact on disease evolution. We demonstrate here that B cells play a pivotal role in host responses against primary DENV infection in mice. After infection, μMT(-/-) mice showed increased viral loads followed by severe disease manifestation characterized by intense thrombocytopenia, hemoconcentration, cytokine production and massive liver damage that culminated in death. In addition, we show that poly and monoclonal anti-DENV-specific antibodies can sufficiently increase viral replication through a suppression of early innate antiviral responses and enhance disease manifestation, so that a mostly non-lethal illness becomes a fatal disease resembling human DHF/DSS. Finally, treatment with intravenous immunoglobulin containing anti-DENV antibodies confirmed the potential enhancing capacity of subneutralizing antibodies to mediate virus infection and replication and induce severe disease manifestation of DENV-infected mice. Thus, our results show that humoral responses unleashed during DENV infections can exert protective or pathological outcomes and provide insight into the pathogenesis of this important human pathogen.
536 _ _ |a 899 - ohne Topic (POF4-899)
|0 G:(DE-HGF)POF4-899
|c POF4-899
|f POF IV
|x 0
588 _ _ |a Dataset connected to DataCite
650 _ 7 |a Cytokines
|2 NLM Chemicals
650 _ 2 |a Animals
|2 MeSH
650 _ 2 |a Antibody-Dependent Enhancement
|2 MeSH
650 _ 2 |a B-Lymphocytes: immunology
|2 MeSH
650 _ 2 |a Cytokines: blood
|2 MeSH
650 _ 2 |a Death
|2 MeSH
650 _ 2 |a Dengue: immunology
|2 MeSH
650 _ 2 |a Dengue: pathology
|2 MeSH
650 _ 2 |a Dengue Virus: immunology
|2 MeSH
650 _ 2 |a Immunity, Innate
|2 MeSH
650 _ 2 |a Liver: pathology
|2 MeSH
650 _ 2 |a Mice, Inbred C57BL
|2 MeSH
650 _ 2 |a Mice, Knockout
|2 MeSH
650 _ 2 |a Thrombocytopenia
|2 MeSH
650 _ 2 |a Viral Load
|2 MeSH
700 1 _ |a Fagundes, Caio T.
|b 1
700 1 _ |a Valadão, Deborah F.
|b 2
700 1 _ |a Ávila, Thiago V.
|b 3
700 1 _ |a Cisalpino, Daniel
|b 4
700 1 _ |a Rocha, Rebeca F.
|b 5
700 1 _ |a Secchim Ribeiro, Lucas
|0 P:(DE-2719)9001782
|b 6
|u dzne
700 1 _ |a Ascenção, Fernando R.
|b 7
700 1 _ |a Kangussu, Lucas M.
|b 8
700 1 _ |a Junior, Celso M. Q.
|b 9
700 1 _ |a Astigarraga, Ruiz G.
|b 10
700 1 _ |a Gouveia, Frederico L.
|b 11
700 1 _ |a Silva, Tarcília A.
|b 12
700 1 _ |a Bonaventura, Daniela
|b 13
700 1 _ |a de Almeida Sampaio, Divaldo
|b 14
700 1 _ |a Leite, Ana Cristina L.
|b 15
700 1 _ |a Teixeira, Mauro M.
|b 16
700 1 _ |a Souza, Danielle G.
|b 17
773 _ _ |a 10.1007/s00430-014-0334-5
|g Vol. 203, no. 4, p. 231 - 250
|0 PERI:(DE-600)1462140-X
|n 4
|p 231 - 250
|t Medical microbiology and immunology
|v 203
|y 2014
|x 0300-8584
856 4 _ |u https://pub.dzne.de/record/284095/files/DZNE-2026-00103_Restricted.pdf
856 4 _ |u https://pub.dzne.de/record/284095/files/DZNE-2026-00103_Restricted.pdf?subformat=pdfa
|x pdfa
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 6
|6 P:(DE-2719)9001782
913 1 _ |a DE-HGF
|b Programmungebundene Forschung
|l ohne Programm
|1 G:(DE-HGF)POF4-890
|0 G:(DE-HGF)POF4-899
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-800
|4 G:(DE-HGF)POF
|v ohne Topic
|x 0
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2024-12-09
|w ger
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2024-12-09
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-09
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-09
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b MED MICROBIOL IMMUN : 2022
|d 2024-12-09
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-09
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-09
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-09
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2024-12-09
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-09
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2024-12-09
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2024-12-09
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-09
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-09
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b MED MICROBIOL IMMUN : 2022
|d 2024-12-09
920 _ _ |l yes
980 _ _ |a journal
980 _ _ |a I:(DE-2719)1040260
980 1 _ |a EXTERN4VITA

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21